DengYueMed

Independent Intelligence on Global Oncology & Rare Disease Markets

Policy · Innovation · Market Access · Competitive Strategy

Focused coverage across FDA · EMA · NMPA · Global Biopharma Markets

---

Lead Analysis

Global Pharmaceutical Supply Chain Risk: Why On-Time Delivery and Compliance Are Replacing Price as Core Procurement Metrics

March 03, 2026

In global pharmaceutical procurement, reliability, compliance, and delivery predictability are increasingly replacing price as the primary evaluation metrics.

Read Full Analysis →

---

Rare Diseases

• The Rise of China's Rare Disease Drugs: From Follower to Emerging Global Leader
  February 27, 2026
• Why Humanity Continues to Invest in Orphan Drug Research — Despite Only 5% of Rare Diseases Being Treatable
  February 27, 2026

View All →

Oncology

View All →

Regulatory

View All →

Supply Chain

• Global Pharmaceutical Supply Chain Risk: Why On-Time Delivery and Compliance Are Replacing Price as Core Procurement Metrics
  March 03, 2026
• From Price to Reliability: How China Is Reshaping Global Pharmaceutical Procurement
  March 02, 2026
• When Patients Can’t Find Their Medicine: What Is Changing in China’s Pharmaceutical Supply Chain?
  February 28, 2026

View All →

---

Market Watch

• FDA / EMA / NMPA Updates
• Rare Disease Policy
• Oncology Innovation
• API & Manufacturing Trends

---

© 2026 DengYueMed. Independent pharmaceutical intelligence platform.